An interventional study of BUFY02 eye drops in single-dose containers and TRB02 eye drops in single-dose containers in Dry Eye Disease, sponsored by TRB Chemedica International SA. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by TRB Chemedica International SA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Dry Eye Syndromes with a site in Austria — 4 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Austria.
Among the 36 studies in Dry Eye Syndromes with a site in Austria, this one is the 5th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 29th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →4 of the 36 studies in Dry Eye Syndromes with a site in Austria are open now. Recruiting first, the newest first:
Vienna Institute for Research in Ocular Surgery · Sites in Austria
Ages 18+
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
Medical University of Vienna · Sites in Austria
Ages 45–99
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 40 across the 31 interventional studies, 30 across the 5 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 36 have an industry lead sponsor. The 10 most frequent:
TRB Chemedica International SA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
TRB Chemedica International SA has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
3 of the studies in Dry Eye Syndromes with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02585414Medical University of ViennaAssessment of TFT by OCT in Healthy Subjects and Subjects With DES | 2026-12 |
| NCT05865457TRB Chemedica International SAEfficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT07809022Medical University of ViennaTemporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Dry Eye Syndromes with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this interventional investigation is to compare BUFY02 with TRB02 in the treatment of patients with dry eye disease. The main questions it aims to answer are:
Participants will be asked to:
Researchers will compare BUFY02 to TRB02 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.3% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.45 mL
Device: BUFY02 eye drops in single-dose containers
0.3% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.45 mL
Device: TRB02 eye drops in single-dose containers
1 to 2 drops in each eye, as often as needed
1 to 2 drops in each eye, as often as needed
Signs
Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome)
Time frame: Day 28
Symptoms
Change from baseline in Ocular Surface Disease Index
Time frame: Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.
Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 19 months is above that.
Counting every sponsor, half of 314 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TRB Chemedica International SA